Hong Kong Offers New Capital Markets Opportunity for Life Sciences and Healthcare Companies

Published date13 March 2018
Law FirmDorsey & Whitney LLP
AuthorMichelle Ng,Janet Wong,Simon Chan,Kenneth Kwok,Candy Pang
Subject MatterLife Sciences,China,Listing Standards,NYSE,Capital Markets,CFDA,Hong Kong,Listing Rules,Hong Kong Stock Exchange,Health Care Providers,Institutional Investors,Regulatory Oversight,New Rules

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT